Methylation Linear Discriminant Analysis for Identifying Differentially Methylated CpG Islands
Author Information
Author(s): Dai Wei, Teodoridis Jens M, Graham Janet, Zeller Constanze, Huang Tim HM, Yan Pearlly, Vass J Keith, Brown Robert, Paul Jim
Primary Institution: Imperial College, Hammersmith Hospital, London, UK
Hypothesis
Can Methylation Linear Discriminant Analysis (MLDA) effectively identify differentially methylated loci in ovarian cancer cell lines?
Conclusion
MLDA successfully identified 115 differentially methylated loci between cisplatin sensitive and resistant ovarian cancer cell lines.
Supporting Evidence
- MLDA identified 115 differentially methylated loci.
- 23 out of 26 loci were validated by independent methods.
- MLDA showed lower misclassification error compared to other methods.
Takeaway
Researchers created a new method to find changes in DNA that can help understand cancer better, and it worked well in tests.
Methodology
MLDA uses linear regression models on log-transformed hybridisation data to determine methylation status.
Potential Biases
Potential bias from the reliance on specific reference sequences for unmethylation.
Limitations
The study may not account for all sources of variation in methylation status due to cross-hybridisation.
Participant Demographics
Ovarian cancer cell lines, including both cisplatin sensitive and resistant types.
Statistical Information
P-Value
8.8 × 10^-3
Statistical Significance
p < 0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website